Venetoclax with azacitidine for newly diagnosed AML
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a combination of oral venetoclax and injected azacitidine for adults who are newly diagnosed with acute myeloid leukemia (AML) and cannot have standard strong chemotherapy. The goal is to see how well this treatment works and what side effects it may cause.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be newly diagnosed with acute myeloid leukemia (AML) and have not received any prior treatment for it.
- Standard strong chemotherapy is not an option for you (your doctor has said you can't have it).
- You must be at least 18 years old.
- Your daily activity level (performance status) should be within a certain range: if you are 75 or older, you should be able to carry out daily activities with little or no help (ECOG 0-2); if you are 18-74, you should be able to function with some help (ECOG 0-3).
- You should not have had another cancer in the last 2 years (except for some low-risk types).
- In the last 30 days, you have not taken any experimental drug, and in the last 7 days, you have not taken strong CYP3A inducers (medications that can interact with the study drug).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how a standard AML treatment plan affects a person’s disease status over time. It focuses on newly diagnosed adults who cannot safely get intensive chemotherapy, using oral venetoclax plus azacitidine.
This trial studies whether adding venetoclax to either azacitidine or decitabine can treat acute myeloid leukemia (AML) when earlier “hypomethylating” treatment has stopped working. You might be a candidate if you’ve already tried azacitidine or decitabine for a related blood condition and it failed, and you meet the health-safety limits.
This Phase 2 study tests whether the combination of azacitidine and venetoclax can help people with acute myeloid leukemia (AML) who can’t handle standard intensive chemotherapy, including some relapsed or refractory cases. It also involves extra optional-style lab testing on your leukemia (bio-banking and “-omics” profiling) to learn which drug sensitivities may matter.
This trial tests a new combination of venetoclax plus a chemotherapy regimen (called CACAG) against a standard chemotherapy regimen (3+7) for adults with newly diagnosed intermediate- or high-risk AML. The goal is to see if the new combination works better.
This trial tests a combination of three oral medications (chidamide, venetoclax, and azacitidine) for people newly diagnosed with acute myeloid leukemia (AML) who cannot receive strong chemotherapy. The goal is to see if this gentler treatment can work well with fewer side effects.
This Phase 2 trial compares two treatment approaches for people newly diagnosed with a specific type of AML (bone marrow cancer) that has an NPM1 mutation: venetoclax plus azacitidine versus intensive (strong) chemotherapy. It aims to see which plan works better and is safer for “fit” patients.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.